Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Isenberg

Showing results (41-50 of 280) with videos related to

Pageof 28
Sort By:
Rheumatology (Oxford, England)|March 4, 2009
Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletionBryan R Whelan, David A Isenberg
Rheumatology (Oxford, England)|December 31, 2009
Re-classifying myositisShabina M Sultan, David A Isenberg
Clinical and Experimental Medicine|March 5, 2020
"Mixed connective tissue disease": a condition in search of an identityMarta R Alves, David A Isenberg
Clinical and Experimental Rheumatology|April 16, 2013
Antinuclear antibodies seroconversion in 100 patients with lupusAngeles Acosta-Mérida, David A Isenberg
Expert Opinion on Biological Therapy|November 20, 2020
The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?Ana Lorenzo-Vizcaya, David A Isenberg
Therapeutic Advances in Musculoskeletal Disease|March 28, 2017
Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulnessSara Guerreiro Castro, David A Isenberg
Rheumatology (Oxford, England)|November 13, 2016
Comment on: Musculoskeletal complication of haematological disease: ReplyDavid A Isenberg, Sandra A Morais
Expert Review of Clinical Immunology|May 19, 2010
Childhood- and adult-onset lupus: an update of similarities and differencesEva D Papadimitraki, David A Isenberg
Journal of Thrombosis and Haemostasis : JTH|January 3, 2020
Use of direct oral anticoagulants in antiphospholipid syndrome: ReplyHannah Cohen, Maria Efthymiou, David A Isenberg
Current Opinion in Rheumatology|December 5, 2006
Syndromes and complications of interferon therapyFrances A Y Borg, David A Isenberg
Pageof 28

Showing results (41-50 of 280) with videos related to

Sort By:
Pageof 28
Rheumatology (Oxford, England)|March 4, 2009
Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletionBryan R Whelan, David A Isenberg
Rheumatology (Oxford, England)|December 31, 2009
Re-classifying myositisShabina M Sultan, David A Isenberg
Clinical and Experimental Medicine|March 5, 2020
"Mixed connective tissue disease": a condition in search of an identityMarta R Alves, David A Isenberg
Clinical and Experimental Rheumatology|April 16, 2013
Antinuclear antibodies seroconversion in 100 patients with lupusAngeles Acosta-Mérida, David A Isenberg
Expert Opinion on Biological Therapy|November 20, 2020
The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?Ana Lorenzo-Vizcaya, David A Isenberg
Therapeutic Advances in Musculoskeletal Disease|March 28, 2017
Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulnessSara Guerreiro Castro, David A Isenberg
Rheumatology (Oxford, England)|November 13, 2016
Comment on: Musculoskeletal complication of haematological disease: ReplyDavid A Isenberg, Sandra A Morais
Expert Review of Clinical Immunology|May 19, 2010
Childhood- and adult-onset lupus: an update of similarities and differencesEva D Papadimitraki, David A Isenberg
Journal of Thrombosis and Haemostasis : JTH|January 3, 2020
Use of direct oral anticoagulants in antiphospholipid syndrome: ReplyHannah Cohen, Maria Efthymiou, David A Isenberg
Current Opinion in Rheumatology|December 5, 2006
Syndromes and complications of interferon therapyFrances A Y Borg, David A Isenberg
Pageof 28